Emerging Company Profile
Luminary: turning cell engineering tools into therapies
Former B-MoGen execs leverage experience in non-viral cell engineering tools to form therapeutic start-up
Luminary’s founders are taking advantage of their experience in developing non-viral genome engineering tools to develop engineered cell therapies.
Luminary is parlaying its founders’ experience in non-viral genome engineering to build a pipeline of cell therapies that are faster to develop and more cost-effective than those that depend on virus-based technologies.
Luminary Therapeutics Inc. was carved out